首页/数据集/Outcomes of participants, assigned treatment duration and HCV genotype*.

Outcomes of participants, assigned treatment duration and HCV genotype*.

Figshare2017-07-08 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/Outcomes_of_participants_assigned_treatment_duration_and_HCV_genotype_sup_sup_/5184181 数据链接链接失效反馈

官方服务：

资源简介：

Outcomes of participants, assigned treatment duration and HCV genotype*.

应用场景：

创建时间：

2017-07-08

丙型肝炎治疗

用药安全

Abstract INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered

DataCite Commons2020-08-29 更新70

A Study to Assess the Efficacy of the Sofosbuvir/Daclatasvir Combination as a Pan-genotypic Treatment for Hepatitis C without HCV Genotype Determination

丙型肝炎治疗

药物疗效评估

Background: Viral hepatitis C (HCV) is a global health challenge affecting at least 3.3% of the world’s population. Saharan Africa still battles with the under-diagnosis and poor access to diagnostic

DataCite Commons2024-02-12 更新50

Baseline characteristics of patients with HCV Genotype 2 who started treatment with PegIFN/RBV.

丙型肝炎治疗

患者基线特征

Baseline characteristics of patients with HCV Genotype 2 who started treatment with PegIFN/RBV.

NIAID Data Ecosystem30

丙型肝炎治疗

直接抗病毒药物荟萃分析

This data archive contains the following 7 files relating to treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: - Supplementary figure 1: Thematic map

NIAID Data Ecosystem50

Characteristics of genotype 4 hepatitis C patients treated with simeprevir plus sofosbuvir with or without ribavirin.

丙型肝炎治疗

病毒药物疗效

Characteristics of genotype 4 hepatitis C patients treated with simeprevir plus sofosbuvir with or without ribavirin.

NIAID Data Ecosystem40